| Execution period | Up to December 31, 2030 |
|---|
NSE filing, NSE: KSHINTL. Summary written from the filing by ALFA Finder's alert engine.
KSH International Ltd: key numbers
- Share price
- ₹928.60
- Market cap
- ₹6,292 Cr
- Revenue (annual)
- ₹3,107 Cr
- Net profit (annual)
- ₹110.1 Cr
- P/E (TTM)
- 48.5×Sector 52.8×
- Promoter holding
- 74.58%+0.00% QoQ
- FII holding
- 6.60%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from KSH International Ltd
All →KSH International Business Update
KSH International received PGCIL manufacturer approval to produce CTC, PICC, and BPICC for 765 kV transformers/reactors. The Supa Facility can now supply conductors for POWERGRID projects.
KSH International Board Meeting Date
KSH International will hold a board meeting on November 04, 2026, to consider and approve unaudited financial results for the quarter ended September 30, 2026.
KSH International Management Change
KSH International appointed Mr. Amitabha Mukhopadhyay as an Additional Non-Executive Independent Director. Mr. Ajay Shriram Patil resigned as an Independent Director.
KSH International Annual General Meeting
KSH International Limited held its 47th Annual General Meeting on September 15, 2026, and has submitted the summary of proceedings to the exchange.
KSH International Production Started
KSH International Limited received Consent to Operate from the Maharashtra Pollution Control Board. This approval enables a total manufacturing capacity of 28,800 MTPA at its Supa Facility.
- manufacturing capacity
- 28800.0 MTPA
KSH International Regulatory Approval
KSH International received a 'Consent to Operate' from the Maharashtra Pollution Control Board for its Supa Facility. This approval authorizes a total manufacturing capacity of 28,800 MTPA.
- manufacturing capacity
- 28800.0 MTPA
Other regulatory approval announcements
All →Grasim Industries Regulatory Approval
CCI approved subsidiary ABReN's acquisition of 100% of Solenergi Power from Shell Overseas. The approval clears a regulatory condition for the deal announced on 13 July 2026.
Vedavaag Systems Regulatory Approval
Vedavaag's WOS received IRDAI Certificate of Registration to act as Direct Life & General Insurance Broker. The group enters regulated insurance broking activity.
Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
RNFI Services Regulatory Approval
RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.
Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.